Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Phase 1 Terminated 74 enrolled Stemcentrx

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1a/1b study of SC-003 as a single agent and in combination with ABBV-181 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. ABBV-181 is a humanized, recombinant, mAb that binds to cell surface expressed programmed cell death 1 (PD-1).

Timeline

Start: 2015-08
Primary completion: 2019-01-02
Completion: 2019-01-02

Publications

Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 Sep;158(3):640-645. doi: 10.1016/j.ygyno.2020.05.038. Epub 2020 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Budigalimab	Monoclonal antibody	—	Intravenous
Subject	SC-003	Unknown	0.025 mg/kg	Intravenous
Subject	SC-003	Unknown	0.2 mg/kg	Intravenous
Subject	SC-003	Unknown	0.3 mg/kg	Intravenous
Subject	SC-003	Unknown	0.4 mg/kg	Intravenous

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications